TNF and neoplasm: Taking into consideration our findings, the administration of TNF neutralization agents prophylactically or concomitantly with ICB therapy was capable of resolving these shortcomings for ICB immunotherapy, while retaining its anti-tumor efficacy, presenting a strategy that allows for a separation between efficacy and toxicity (Figure 1).